论文部分内容阅读
目的:通过研究并比较前列腺特异性膜抗原(PSMA)基因启动子、增强子和survivin基因启动子在不同前列腺癌细胞系(LNCaP和PC-3细胞)中的转录活性,为前列腺癌的靶向性基因治疗提供依据。方法:采用PCR扩增PSMA基因的启动子、增强子和survivin基因启动子,分别克隆入pGL3-Basic,脂质体转染前列腺癌细胞和张氏肝细胞,检测各启动子在细胞中的转录活性。结果:survivin基因启动子在前列腺癌细胞中均具有较强活性,均明显高于PSMA启动子/增强子,其中S2pro启动活性最强,达到CMV启动子活性的1/3,然而,survivin启动子及PSMA启动子/增强子在肝细胞系中几乎不表达。结论:survivin启动子在前列腺癌细胞中具有较强启动活性,可望成为新的前列腺癌靶向性基因治疗工具。
OBJECTIVE: To study and compare the transcriptional activity of PSMA promoter, enhancer and survivin promoter in different prostate cancer cell lines (LNCaP and PC-3 cells) Gene therapy basis. Methods: The promoters of PSMA gene, enhancer and survivin gene promoter were amplified by PCR, cloned into pGL3-Basic, and then transfected into prostate cancer cells and Chang’s hepatocytes by lipofectamine 2000 respectively. The transcription of each promoter in the cells active. Results: The survivin gene promoter was highly active in prostate cancer cells, which was significantly higher than that of PSMA promoter / enhancer, of which S2pro had the strongest promoter activity and reached 1/3 of the CMV promoter activity. However, survivin promoter And PSMA promoter / enhancer are hardly expressed in hepatocyte lines. Conclusion: The survivin promoter has strong priming activity in prostate cancer cells and is expected to become a new tool for targeted gene therapy of prostate cancer.